Apply for Patent – Protect your earth-moving ideas with PowerPatent software service for Online Patent Application
The Genentech, Inc., , Aimm Therapeutics B.V. patent solves the following problem:
Program-positive microorganisms cause many systemic infections. An important member of the gram-positive pathogens are Staphylococcus aureus (S. aureus). 20% of the population is a long-term carrier of S. aureus. S. aureus can cause a range of illnesses from minor skin infections, such as pimples, impetigo (may also be caused by streptococcus pyogenes), boils, cellulitis folliculitis, furuncles, carbuncles, scalded skin syndrome and abscesses , life-threatening diseases such as pneumonia, meningitis, osteomyelitis, endocarditis, Toxic shock syndrome (TSS), and septicemia. S. aureus is capable of infecting all kinds of organs and tissues. S. aureus infection occur in immunocompetent as well as in immune compromised people. 50% of infections in US intensive unit care causing pathogen. Three hundred thousand S. aureus infections every year, resulting in 12,000 deaths, reported in the US (see also Moran et al. NEMJ 355, 666-674 (2006)).
Our analysis of this patent is as follows:
Genentech, Inc., , Aimm Therapeutics B.V.’s patent US 9458228 B2 deals with Gram-positive bacteria specific binding compounds.
The present invention provides improved value compounds can specifically bind gram-positive bacteria. Binding compounds which are fully human, so that therapeutic applications of human individuals.
The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.